logo-loader

Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

Last updated: 16:19 09 Jun 2018 EDT, First published: 01:32 09 Jun 2018 EDT

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive Investors the biopharmaceutical company is developing a drug to make 'the new frontier' in cancer therapy safer therapy by developing its antibody to Phase II studies. 

Durrant says Humanigen's focus is on making chimeric antigen receipter T-cell (CAR-T) therapy safer and more effective, that minimizes the requirement to be in a hospital. Durrant says Humanigen's antibody called lenzilumab can block a molecule called GM-CSF, which is the key master switch that leads to brain inflammation, amoung other things. Durrant says Humanigen is excited to begin Phase II studies to test this, and are partnering with leading insitutions to begin clinical trials. Durrant says Humanigen is hoping to begin Phase II this year once the company completes fundraising. 

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 48 minutes ago